Navigation Links
Cellular force that drives allergy and asthma can be blocked by interferon
Date:6/16/2014

DALLAS June 16, 2014 A mechanism that could underlie the development of cells that drive asthma and allergies has been uncovered by immunology researchers at UTSouthwestern Medical Center.

Asthma and allergies are both driven by an inappropriate activation of the immune system, primarily a subtype of white blood cells known as T helper 2 cells, or Th2 cells. These cells are normally responsible for defense against parasites, but are also the main culprits behind the symptoms of asthma and allergies.

Dr. David Farrar, Associate Professor of Immunology and Molecular Biology at UTSouthwestern, and his team found that the antiviral molecules known as type I interferons (IFNs) block the development of these allergy- and asthma-driving Th2 cells.

"The fact that interferon could stop the activation of these harmful cells was of particular interest because interferons are already approved by the Food and Drug Administration for the treatment of other diseases, such as multiple sclerosis and hepatitis," said Dr. Farrar, who holds the J. Wayne Streilein, M.D. Professorship in Immunology.

The work, published in the Journal of Immunology, could eventually give rise to new therapies.

To demonstrate the prevalence of asthma, in the United States about 13 percent of adults nearly 30 million people have received a diagnosis of asthma. This frequency compares to 11 percent who have been diagnosed with heart disease and 8 percent who have had any form of cancer, according to the Centers for Disease Control and Prevention. Asthma is reported more often among women than men, among Caucasians, and in families with limited economic resources. Allergies, too, are prevalent, with more than 17.5 million people suffering from hay fever in the U.S.

The development of Th2 cells is stimulated by a particular immune molecule that triggers the production of a protein called GATA3. Frequently referred to as the master regulator of Th2 cell development, GATA3 turns on the genes that distinguish Th2 cells from other cell types, including other T cells.

Dr. Farrar's group found that type I IFNs block this process by targeting a part of the GATA3 gene known as exon 1a and turning it off, thereby inhibiting the production of the GATA3 protein and, consequently, the development of Th2 cells.

"Targeting this pathway may lead to permanent tolerance of these cells to allergens," said Dr. Farrar. "We are currently pursuing studies that may lead to clinical trials that will determine whether interferon can be used to treat allergic asthma patients."

Dr. Farrar's lab studies how a collective group of proteins called cytokines regulate immune responses. Type 1 interferon, the first immune cytokine discovered, is one of the very first lines of defense against viruses. The protein was initially identified based on its ability to inhibit influenza virus. Since then, scientists have discovered that almost any cell in the body can secrete interferon if it becomes infected with certain viruses, and that most cells can respond to interferon.


'/>"/>
Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Cellular pathway linked to diabetes, heart disease
2. Why omega-3 oils help at the cellular level
3. Discovery explains how cellular pathways converge to regulate food intake and body weight
4. New technique reveals cross-talk between 2 essential cellular processes
5. LA BioMed investigator, Dr. Yutaka Niihara, developing novel cellular therapy
6. Molecular switch identified that controls key cellular process
7. MedScope Announces Changes to the Medical Alarm Industry, Bringing it into the Cellular Age
8. The new age of proteomics: An integrative vision of the cellular world
9. Research explores road signs on the intracellular highway
10. Extracellular vesicles may open new opportunities for brain cancer diagnosis and treatment
11. Study: HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cellular force that drives allergy and asthma can be blocked by interferon
(Date:12/8/2016)... ... , ... CURE Media Group, the nation’s leading digital and print media enterprise ... Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael J. ... Group is honored to team up with Upstage Lung Cancer in order to make ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... 08, 2016 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that it had joined the Pharmaceutical Supply Chain Initiative ... to unite pharmaceutical and healthcare companies that share a vision of better, social, ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
(Date:12/8/2016)... Francisco, California (PRWEB) , ... December 08, 2016 , ... ... coaches, has raised an $18M Series B led by Canvas Ventures . Other ... the capital to scale its mobile platform to serve more consumers who are managing ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Texas , Dec. 8, 2016 ... program that brings leading-edge laboratory services and management ... United States , allowing more doctors and ... health care management solutions. Logo - ... Hospital systems, under pressure to contain ...
(Date:12/8/2016)... , Dec. 8, 2016 A Small ... the National Institutes of Health (NIH) to ... University.  The grant will seek to ... head device, which utilizes electromagnetic waves to treat Alzheimer,s ... this novel technology to possibly treat other neurologic disorders ...
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced ... Corporate Equality Index (CEI). This is the ninth time ... been designated as a Best Place to Work for ... the CEI is a national benchmarking report on corporate ... gay, bisexual and transgender (LGBT) employees. ...
Breaking Medicine Technology: